サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1339255

ハンセン病治療薬市場、シェア、規模、動向、産業分析レポート：薬剤クラス別、疾患タイプ別、投与経路別、流通チャネル別、地域別、セグメント別予測、2023年～2032年

Leprosy Treatment Market Share, Size, Trends, Industry Analysis Report, By Drug Class ; By Disease Type; By Route of Administration; By Distribution Channel; By Region; Segment Forecast, 2023 - 2032

出版日
ページ情報
英文 112 Pages
納期
即日から翌営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
ハンセン病治療薬市場、シェア、規模、動向、産業分析レポート：薬剤クラス別、疾患タイプ別、投与経路別、流通チャネル別、地域別、セグメント別予測、2023年～2032年
出版日: 2023年07月23日
発行: Polaris Market Research
ページ情報: 英文 112 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

Polaris Market Research社の最新調査によると、世界のハンセン病治療薬市場規模は2032年までに50億33万米ドルに達する見込みです。本レポートでは、現在の市場力学を詳細に洞察し、将来の市場成長に関する分析を提供しています。

ハンセン病治療薬の需要は、皮膚疾患の罹患率の増加により急速に拡大しています。乾癬やハンセン病のような皮膚疾患の有病率は、中国やインドのような国々で増加しており、これが市場に拍車をかけています。世界保健機関（WHO）によると、約120カ国でハンセン病患者が発生しており、年間20万件以上が報告されています。何億人もの人々が皮膚NTDsに罹患しています。

さらに、NTDのひとつであるハンセン病は、遠隔地の農村部に住む主に社会から疎外された人々の生活水準を損ない、計り知れない不快感、苦しみ、汚名、精神的苦痛を与えています。高い発生率から、世界の一部の地域では高い発生率と高い感染率の両方が見られます。過去20年間で、WHOは約1,600万人のハンセン病患者が治療を受けたと推定しています。そのため、皮膚病の有病率の上昇とNTDの蔓延がハンセン病治療薬への需要を高め、予測期間における市場の成長を牽引しています。

WHOによると、NTDsへの介入を必要とする人の数は過去10年間で25%減少しており、2020年から2021年の間に約8,000万人減少します。さらに、障害を伴う生活年数で測定した疾病負担も一貫して減少しています。2016年から2019年にかけて、毎年10億人以上が治療を受けています。2022年末までに、47カ国が少なくとも1つのNTDを排除しました。

しかし、COVID-19パンデミックはNTDプログラムに深刻な影響を及ぼし、その結果、コミュニティベースの介入の実施が減少し、ヘルスケア施設が提供するサービスへのアクセスが制限され、医療用品のサプライチェーンにも悪影響が及び、この有望な動向は崩壊しました。その結果、2019年から2020年にかけて、NTDsの治療を受ける人が34%減少しました。

ハンセン病治療薬市場レポートハイライト

ハンセン病治療薬の第一選択薬がダプソンであることから、注射剤投与ルートセグメントは予測期間中に大きなCAGRで成長すると予測されます。

抗結核薬は、リファンピンなどの薬剤が結核とハンセン病の両方を治療することから、予測期間中に大きな市場シェアを占めると予想されます。

アジア太平洋地域は、有病率の上昇に加え、治療を支援する政府プログラムにより、予測期間中にかなりのCAGRで成長すると予想されます。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 調査手法

第4章 世界のハンセン病治療薬市場に関する洞察

  • ハンセン病治療薬- 業界スナップショット
  • ハンセン病治療薬市場力学
    • 促進要因と機会
      • 技術の進歩
      • ヘルスケアにおけるハンセン病治療薬技術の利用の増加
    • 抑制要因と課題
      • デジタル化の進展により市場の成長が制限される
  • PESTLE分析
  • ハンセン病治療薬業界の動向
  • バリューチェーン分析
  • COVID-19感染症の影響分析

第5章 世界のハンセン病治療薬市場、薬剤クラス別

  • 主な調査結果
  • イントロダクション
  • 抗菌剤
  • ハンセン病
  • スルホン
  • フェナジン
  • 抗結核薬
  • その他

第6章 世界のハンセン病治療薬市場、疾患タイプ別

  • 主な調査結果
  • イントロダクション
  • パウチバクテリア性ハンセン病
  • 多菌性ハンセン病

第7章 世界のハンセン病治療薬市場、投与経路別

  • 主な調査結果
  • イントロダクション
  • 経口
  • 注射
  • 局所

第8章 世界のハンセン病治療薬市場、流通チャネル別

  • 主な調査結果
  • イントロダクション
  • 病院薬局
  • 小売薬局
  • ドラッグストア
  • オンライン薬局

第9章 世界のハンセン病治療薬市場、地域別

  • 主な調査結果
  • イントロダクション
    • ハンセン病治療薬市場評価、地域別、2019～2032年
  • ハンセン病治療薬市場-北米
    • 北米：ハンセン病治療薬市場、薬剤クラス別、2019～2032年
    • 北米：ハンセン病治療薬市場、流通チャネル別、2019～2032年
    • 北米：ハンセン病治療薬市場、疾患タイプ別、2019～2032年
    • 北米：ハンセン病治療薬市場、投与経路別、2019～2032年
    • ハンセン病治療薬市場-米国
    • ハンセン病治療薬市場- カナダ
  • ハンセン病治療薬市場- 欧州
    • 欧州：ハンセン病治療薬市場、薬剤クラス別、2019～2032年
    • 欧州：ハンセン病治療薬市場、流通チャネル別、2019～2032年
    • 欧州：ハンセン病治療薬市場、疾患タイプ別、2019～2032年
    • 欧州：ハンセン病治療薬市場、投与経路別、2019～2032年
    • ハンセン病治療薬市場- 英国
    • ハンセン病治療薬市場- フランス
    • ハンセン病治療薬市場- ドイツ
    • ハンセン病治療薬市場- イタリア
    • ハンセン病治療薬市場- スペイン
    • ハンセン病治療薬市場- オランダ
    • ハンセン病治療薬市場- ロシア
  • ハンセン病治療薬市場- アジア太平洋
    • アジア太平洋：ハンセン病治療薬市場、薬剤クラス別、2019～2032年
    • アジア太平洋：ハンセン病治療薬市場、流通チャネル別、2019～2032年
    • アジア太平洋：ハンセン病治療薬市場、疾患タイプ別、2019～2032年
    • アジア太平洋：ハンセン病治療薬市場、投与経路別、2019～2032年
    • ハンセン病治療薬市場- 中国
    • ハンセン病治療薬市場- インド
    • ハンセン病治療薬市場- 日本
    • ハンセン病治療薬市場- マレーシア
    • ハンセン病治療薬市場- インドネシア
    • ハンセン病治療薬市場- 韓国
  • ハンセン病治療薬市場-中東およびアフリカ
    • 中東およびアフリカ：ハンセン病治療薬市場、薬剤クラス別、2019～2032年
    • 中東およびアフリカ：ハンセン病治療薬市場、流通チャネル別、2019～2032年
    • 中東およびアフリカ：ハンセン病治療薬市場、疾患タイプ別、2019～2032年
    • 中東およびアフリカ：ハンセン病治療薬市場、投与経路別、2019～2032年
    • ハンセン病治療薬市場- サウジアラビア
    • ハンセン病治療薬市場- 南アフリカ
    • ハンセン病治療薬市場- イスラエル
    • ハンセン病治療薬市場- アラブ首長国連邦
  • ハンセン病治療薬市場-ラテンアメリカ
    • ラテンアメリカ：ハンセン病治療薬市場、薬剤クラス別、2019～2032年
    • ラテンアメリカ：ハンセン病治療薬市場、流通チャネル別、2019～2032年
    • ラテンアメリカ：ハンセン病治療薬市場、疾患タイプ別、2019～2032年
    • ラテンアメリカ：ハンセン病治療薬市場、投与経路別、2019～2032年
    • ハンセン病治療薬市場- メキシコ
    • ハンセン病治療薬市場- ブラジル
    • ハンセン病治療薬市場- アルゼンチン

第10章 競合情勢

  • 拡大と買収の分析
    • 拡大
    • 買収
  • 提携/協業/合意/公開
  • Acme Pharmaceuticals
  • Astra Zeneca
  • Bayer
  • Bristol-Myers
  • Cadila Pharmaceuticals
  • Eli Lily
  • Genetic Pharma
  • GSK
  • IDPL
  • Johnson & Johnson
  • Lark Laboratories
  • Merck
  • Macleods Pharmaceuticals
  • Novartis
  • Pfizer
  • Systopic Laboratories
  • Sanofi
  • Teva Pharmaceutical
図表

List of Tables

  • Table 1 Global Leprosy Treatment Market, by Drug Class, by Region, 2019-2032 (USD Million)
  • Table 2 Global Leprosy Treatment Market, by Disease Type, by Region, 2019-2032 (USD Million)
  • Table 3 Global Leprosy Treatment Market, by Route of Administration, by Region, 2019-2032 (USD Million)
  • Table 4 Global Leprosy Treatment Market, by Distribution Channel, by Region, 2019-2032 (USD Million)
  • Table 5 Leprosy Treatment Market Assessment, By Geography, 2019-2032 (USD Million)
  • Table 6 North America: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 7 North America: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • Table 8 North America: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 9 North America: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 10 U.S.: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 11 U.S.: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • Table 12 U.S.: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 13 U.S.: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 14 Canada: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 15 Canada: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • Table 16 Canada: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 17 Canada: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 18 Europe: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 19 Europe: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • Table 20 Europe: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 21 Europe: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 22 Germany: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 23 Germany: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • Table 24 Germany: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 25 Germany: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 26 France: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 27 France: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • Table 28 France: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 29 France: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 30 UK: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 31 UK: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • Table 32 UK: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 33 UK: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 34 Italy: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 35 Italy: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • Table 36 Italy: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 37 Italy: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 38 Netherlands: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 39 Netherlands: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • Table 40 Netherlands: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 41 Netherlands: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 42 Spain: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 43 Spain: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • Table 44 Spain: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 45 Spain: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 46 Russia: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 47 Russia: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • Table 48 Russia: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 49 Russia: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 50 Asia Pacific: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 51 Asia Pacific: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • Table 52 Asia Pacific: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 53 Asia Pacific: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 54 China: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 55 China: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • Table 56 China: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 57 China: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 58 Japan: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 59 Japan: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • Table 60 Japan: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 61 Japan: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 62 India: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 63 India: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • Table 64 India: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 65 India: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 66 Indonesia: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 67 Indonesia: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • Table 68 Indonesia: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 69 Indonesia: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 70 Malaysia: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 71 Malaysia: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • Table 72 Malaysia: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 73 Malaysia: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 74 South Korea: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 75 South Korea: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • Table 76 South Korea: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 77 South Korea: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 78 Latin America: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 79 Latin America: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • Table 80 Latin America: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 81 Latin America: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 82 Brazil: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 83 Brazil: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • Table 84 Brazil: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 85 Brazil: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 86 Mexico: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 87 Mexico: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • Table 88 Mexico: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 89 Mexico: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 90 Argentina: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 91 Argentina: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • Table 92 Argentina: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 93 Argentina: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 94 Middle East & Africa: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 95 Middle East & Africa: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • Table 96 Middle East & Africa: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 97 Middle East & Africa: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 98 UAE: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 99 UAE: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • Table 100 UAE: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 101 UAE: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 102 Saudi Arabia: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 103 Saudi Arabia: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • Table 104 Saudi Arabia: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 105 Saudi Arabia: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 106 South Africa: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 107 South Africa: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • Table 108 South Africa: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 109 South Africa: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 110 Israel: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 111 Israel: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • Table 112 Israel: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 113 Israel: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)

List of Figures

  • Figure 1. Global Leprosy Treatment Market, 2019-2032 (USD Million)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Distribution Channel
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Drug Class
  • Figure 7. Global Leprosy Treatment Market, by Drug Class, 2021 & 2030 (USD Million)
  • Figure 8. Market by Distribution Channel
  • Figure 9. Global Leprosy Treatment Market, by Distribution Channel, 2021 & 2030 (USD Million)
  • Figure 10. Market by Disease Type
  • Figure 11. Global Leprosy Treatment Market, by Disease Type, 2021 & 2030 (USD Million)
  • Figure 12. Market by Route of Administration
  • Figure 13. Global Leprosy Treatment Market, by Route of Administration, 2021 & 2030 (USD Million)
目次
Product Code: PM3635

The global Leprosy Treatment market size is expected to reach USD 5,000.33 million by 2032, according to a new study by Polaris Market Research. The report "Leprosy Treatment Market Share, Size, Trends, Industry Analysis Report, By Drug Class (Antibacterial, Leprostatics, Sulfone, Phenazine, Anti-tubercular Drugs, and Others); By Disease Type; By Route of Administration; By Distribution Channel; By Region; Segment Forecast, 2023- 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The demand for leprosy treatment is growing more quickly due to the increasing incidence of skin diseases. The prevalence of skin conditions like psoriasis and leprosy has increased in nations like China and India, which has fueled the market. According to the World Health Organization, around 120 countries have leprosy cases, and more than 200,000 cases are reported yearly. Hundreds of millions of people have skin NTDs.

Additionally, leprosy, an NTD, hurts the standard of living of mainly marginalized populations in remote rural areas and causes immense discomfort, suffering, stigmatization, and mental distress. The prevalence of high occurrences provides that some regions of the world experience both high incidence and high transmission rates. In the past 20 years, the WHO estimates that approximately 16 million leprosy cases have been treated. Therefore, the rising prevalence of skin disease and NTD prevalence has increased the demand for leprosy treatment, driving the market's growth over the forecast period.

As per the WHO, the number of people needing interventions for NTDs has fallen by 25% over the past ten years, by about 80 million people between 2020 and 2021. Additionally, there is a consistent decline in the disease burden measured in years of life with a disability. Between 2016 and 2019, more than one billion individuals received treatment annually. By the end of 2022, 47 nations had eliminated at least one NTD.

However, the COVID-19 pandemic severely affected NTD programs, which resulted in a decrease in the implementation of community-based interventions, a restriction on access to services provided by healthcare facilities, and negative effects on the supply chains for medical supplies, disrupting this promising trend. As a result, between 2019 and 2020, 34% fewer people were treated for NTDs.

Leprosy Treatment Market Report Highlights

The injectable route of administration segment is anticipated to grow at a significant CAGR over the forecast period owing to the drug of first preference for treating leprosy being dapsone.

Anti-tubercular drugs are expected to hold a significant market share over the forecast period due to drugs such as Rifampin treating both TB and leprosy.

Asia-Pacific is expected to grow at a considerable CAGR over the projected period on account of the rising disease prevalence as well as the government programs to support the treatment.

The global players include: Astra Zeneca, Bayer, GSK, Johnson & Johnson, Merck, Pfizer Inc., Systopic Laboratories, Sanofi, and Teva Pharmaceutical.

Polaris Market Research has segmented the Leprosy Treatment market report based on drug class, route of administration, disease type, distribution channel, and region:

Leprosy Treatment, Drug Class Outlook (Revenue - USD Million, 2019 - 2032)

  • Antibacterial
  • Leprostatics
  • Sulfone
  • Phenazine
  • Anti-tubercular Drugs
  • Others

Leprosy Treatment, Route of Administration Outlook (Revenue - USD Million, 2019 - 2032)

  • Oral
  • Injectable
  • Topical

Leprosy Treatment, Disease Type Outlook (Revenue - USD Million, 2019 - 2032)

  • Paucibacillary Leprosy
  • Multibacillary Leprosy

Leprosy Treatment, Distribution Channel Outlook (Revenue - USD Million, 2019 - 2032)

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Online Pharmacies

Leprosy Treatment, Regional Outlook (Revenue - USD Million, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Leprosy Treatment Market Insights

  • 4.1. Leprosy Treatment - Industry Snapshot
  • 4.2. Leprosy Treatment Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Technological advancement
      • 4.2.1.2. Increasing use of Leprosy Treatment technology in healthcare
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Increasing digitization will restrict the market growth
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTLE Analysis
  • 4.5. Leprosy Treatment Industry Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Leprosy Treatment Market, by Drug Class

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • 5.3. Antibacterial
    • 5.3.1. Global Leprosy Treatment Market, by Antibacterial, by Region, 2019-2032 (USD Million)
  • 5.4. Leprostatics
    • 5.4.1. Global Leprosy Treatment Market, by Leprostatics, by Region, 2019-2032 (USD Million)
  • 5.5. Sulfone
    • 5.5.1. Global Leprosy Treatment Market, by Sulfone, by Region, 2019-2032 (USD Million)
  • 5.6. Phenazine
    • 5.6.1. Global Leprosy Treatment Market, by Phenazine, by Region, 2019-2032 (USD Million)
  • 5.7. Anti-tubercular Drugs
    • 5.7.1. Global Leprosy Treatment Market, by Anti-tubercular Drugs, by Region, 2019-2032 (USD Million)
  • 5.8. Others
    • 5.8.1. Global Leprosy Treatment Market, by Others, by Region, 2019-2032 (USD Million)

6. Global Leprosy Treatment Market, by Disease Type

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • 6.3. Paucibacillary Leprosy
    • 6.3.1. Global Leprosy Treatment Market, by Paucibacillary Leprosy, by Region, 2019-2032 (USD Million)
  • 6.4. Multibacillary Leprosy
    • 6.4.1. Global Leprosy Treatment Market, by Multibacillary Leprosy, by Region, 2019-2032 (USD Million)

7. Global Leprosy Treatment Market, by Route of Administration

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • 7.3. Oral
    • 7.3.1. Global Leprosy Treatment Market, by Oral, by Region, 2019-2032 (USD Million)
  • 7.4. Injectable
    • 7.4.1. Global Leprosy Treatment Market, by Injectable, by Region, 2019-2032 (USD Million)
  • 7.5. Topical
    • 7.5.1. Global Leprosy Treatment Market, by Topical, by Region, 2019-2032 (USD Million)

8. Global Leprosy Treatment Market, by Distribution Channel

  • 8.1. Key Findings
  • 8.2. Introduction
    • 8.2.1. Global Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • 8.3. Hospital Pharmacies
    • 8.3.1. Global Leprosy Treatment Market, by Hospital Pharmacies, by Region, 2019-2032 (USD Million)
  • 8.4. Retail Pharmacies
    • 8.4.1. Global Leprosy Treatment Market, by Retail Pharmacies, by Region, 2019-2032 (USD Million)
  • 8.5. Drug Stores
    • 8.5.1. Global Leprosy Treatment Market, by Drug Stores, by Region, 2019-2032 (USD Million)
  • 8.6. Online Pharmacies
    • 8.6.1. Global Leprosy Treatment Market, by Online Pharmacies, by Region, 2019-2032 (USD Million)

9. Global Leprosy Treatment Market, by Geography

  • 9.1. Key findings
  • 9.2. Introduction
    • 9.2.1. Leprosy Treatment Market Assessment, By Geography, 2019-2032 (USD Million)
  • 9.3. Leprosy Treatment Market - North America
    • 9.3.1. North America: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
    • 9.3.2. North America: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
    • 9.3.3. North America: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
    • 9.3.4. North America: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 9.3.5. Leprosy Treatment Market - U.S.
      • 9.3.5.1. U.S.: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 9.3.5.2. U.S.: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 9.3.5.3. U.S.: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
      • 9.3.5.4. U.S.: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 9.3.6. Leprosy Treatment Market - Canada
      • 9.3.6.1. Canada: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 9.3.6.2. Canada: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 9.3.6.3. Canada: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
      • 9.3.6.4. Canada: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • 9.4. Leprosy Treatment Market - Europe
    • 9.4.1. Europe: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
    • 9.4.2. Europe: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
    • 9.4.3. Europe: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
    • 9.4.4. Europe: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 9.4.5. Leprosy Treatment Market - UK
      • 9.4.5.1. UK: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 9.4.5.2. UK: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 9.4.5.3. UK: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
      • 9.4.5.4. UK: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 9.4.6. Leprosy Treatment Market - France
      • 9.4.6.1. France: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 9.4.6.2. France: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 9.4.6.3. France: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
      • 9.4.6.4. France: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 9.4.7. Leprosy Treatment Market - Germany
      • 9.4.7.1. Germany: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 9.4.7.2. Germany: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 9.4.7.3. Germany: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
      • 9.4.7.4. Germany: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 9.4.8. Leprosy Treatment Market - Italy
      • 9.4.8.1. Italy: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 9.4.8.2. Italy: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 9.4.8.3. Italy: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
      • 9.4.8.4. Italy: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 9.4.9. Leprosy Treatment Market - Spain
      • 9.4.9.1. Spain: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 9.4.9.2. Spain: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 9.4.9.3. Spain: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
      • 9.4.9.4. Spain: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 9.4.10. Leprosy Treatment Market - Netherlands
      • 9.4.10.1. Netherlands: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 9.4.10.2. Netherlands: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 9.4.10.3. Netherlands: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
      • 9.4.10.4. Netherlands: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 9.4.11. Leprosy Treatment Market - Russia
      • 9.4.11.1. Russia: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 9.4.11.2. Russia.: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 9.4.11.3. Russia: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
      • 9.4.11.4. Russia: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • 9.5. Leprosy Treatment Market - Asia Pacific
    • 9.5.1. Asia Pacific: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
    • 9.5.2. Asia Pacific: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
    • 9.5.3. Asia Pacific: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
    • 9.5.4. Asia Pacific: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 9.5.5. Leprosy Treatment Market - China
      • 9.5.5.1. China: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 9.5.5.2. China.: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 9.5.5.3. China: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
      • 9.5.5.4. China: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 9.5.6. Leprosy Treatment Market - India
      • 9.5.6.1. India: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 9.5.6.2. India.: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 9.5.6.3. India: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
      • 9.5.6.4. India: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 9.5.7. Leprosy Treatment Market - Japan
      • 9.5.7.1. Japan: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 9.5.7.2. Japan.: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 9.5.7.3. Japan: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
      • 9.5.7.4. Japan: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 9.5.8. Leprosy Treatment Market - Malaysia
      • 9.5.8.1. Malaysia: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 9.5.8.2. Malaysia.: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 9.5.8.3. Malaysia: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
      • 9.5.8.4. Malaysia: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 9.5.9. Leprosy Treatment Market - Indonesia
      • 9.5.9.1. Indonesia: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 9.5.9.2. Indonesia.: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 9.5.9.3. Indonesia: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
      • 9.5.9.4. Indonesia: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 9.5.10. Leprosy Treatment Market - South Korea
      • 9.5.10.1. South Korea: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 9.5.10.2. South Korea.: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 9.5.10.3. South Korea: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
      • 9.5.10.4. South Korea: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • 9.6. Leprosy Treatment Market - Middle East & Africa
    • 9.6.1. Middle East & Africa: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
    • 9.6.2. Middle East & Africa: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
    • 9.6.3. Middle East & Africa: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
    • 9.6.4. Middle East & Africa: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 9.6.5. Leprosy Treatment Market - Saudi Arabia
      • 9.6.5.1. Saudi Arabia: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 9.6.5.2. Saudi Arabia: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 9.6.5.3. Saudi Arabia: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
      • 9.6.5.4. Saudi Arabia: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 9.6.6. Leprosy Treatment Market - South Africa
      • 9.6.6.1. South Africa: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 9.6.6.2. South Africa: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 9.6.6.3. South Africa: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
      • 9.6.6.4. South Africa: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 9.6.7. Leprosy Treatment Market - Israel
      • 9.6.7.1. Israel: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 9.6.7.2. Israel: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 9.6.7.3. Israel: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
      • 9.6.7.4. Israel: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 9.6.8. Leprosy Treatment Market - UAE
      • 9.6.8.1. UAE: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 9.6.8.2. UAE: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 9.6.8.3. UAE: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
      • 9.6.8.4. UAE: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • 9.7. Leprosy Treatment Market - Latin America
    • 9.7.1. Latin America: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
    • 9.7.2. Latin America: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
    • 9.7.3. Latin America: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
    • 9.7.4. Latin America: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 9.7.5. Leprosy Treatment Market - Mexico
      • 9.7.5.1. Mexico: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 9.7.5.2. Mexico: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 9.7.5.3. Mexico: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
      • 9.7.5.4. Mexico: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 9.7.6. Leprosy Treatment Market - Brazil
      • 9.7.6.1. Brazil: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 9.7.6.2. Brazil: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 9.7.6.3. Brazil: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
      • 9.7.6.4. Brazil: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 9.7.7. Leprosy Treatment Market - Argentina
      • 9.7.7.1. Argentina: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 9.7.7.2. Argentina: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 9.7.7.3. Argentina: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
      • 9.7.7.4. Argentina: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)

10. Competitive Landscape

  • 10.1. Expansion and Acquisition Analysis
    • 10.1.1. Expansion
    • 10.1.2. Acquisitions
  • 10.2. Partnerships/Collaborations/Agreements/Exhibitions
  • 11.1. Acme Pharmaceuticals
    • 11.1.1. Company Overview
    • 11.1.2. Financial Performance
    • 11.1.3. Product Benchmarking
    • 11.1.4. Recent Development
  • 11.2. Astra Zeneca
    • 11.2.1. Company Overview
    • 11.2.2. Financial Performance
    • 11.2.3. Product Benchmarking
    • 11.2.4. Recent Development
  • 11.3. Bayer
    • 11.3.1. Company Overview
    • 11.3.2. Financial Performance
    • 11.3.3. Product Benchmarking
    • 11.3.4. Recent Development
  • 11.4. Bristol-Myers
    • 11.4.1. Company Overview
    • 11.4.2. Financial Performance
    • 11.4.3. Product Benchmarking
    • 11.4.4. Recent Development
  • 11.5. Cadila Pharmaceuticals
    • 11.5.1. Company Overview
    • 11.5.2. Financial Performance
    • 11.5.3. Product Benchmarking
    • 11.5.4. Recent Development
  • 11.6. Eli Lily
    • 11.6.1. Company Overview
    • 11.6.2. Financial Performance
    • 11.6.3. Product Benchmarking
    • 11.6.4. Recent Development
  • 11.7. Genetic Pharma
    • 11.7.1. Company Overview
    • 11.7.2. Financial Performance
    • 11.7.3. Product Benchmarking
    • 11.7.4. Recent Development
  • 11.8. GSK
    • 11.8.1. Company Overview
    • 11.8.2. Financial Performance
    • 11.8.3. Product Benchmarking
    • 11.8.4. Recent Development
  • 11.9. IDPL
    • 11.9.1. Company Overview
    • 11.9.2. Financial Performance
    • 11.9.3. Product Benchmarking
    • 11.9.4. Recent Development
  • 11.10. Johnson & Johnson
    • 11.10.1. Company Overview
    • 11.10.2. Financial Performance
    • 11.10.3. Product Benchmarking
    • 11.10.4. Recent Development
  • 11.11. Lark Laboratories
    • 11.11.1. Company Overview
    • 11.11.2. Financial Performance
    • 11.11.3. Product Benchmarking
    • 11.11.4. Recent Development
  • 11.12. Merck
    • 11.12.1. Company Overview
    • 11.12.2. Financial Performance
    • 11.12.3. Product Benchmarking
    • 11.12.4. Recent Development
  • 11.13.Macleods Pharmaceuticals
    • 11.13.1. Company Overview
    • 11.13.2. Financial Performance
    • 11.13.3. Product Benchmarking
    • 11.13.4. Recent Development
  • 11.14. Novartis
    • 11.14.1. Company Overview
    • 11.14.2. Financial Performance
    • 11.14.3. Product Benchmarking
    • 11.14.4. Recent Development
  • 11.15. Pfizer
    • 11.15.1. Company Overview
    • 11.15.2. Financial Performance
    • 11.15.3. Product Benchmarking
    • 11.15.4. Recent Development
  • 11.16. Systopic Laboratories
    • 11.16.1. Company Overview
    • 11.16.2. Financial Performance
    • 11.16.3. Product Benchmarking
    • 11.16.4. Recent Development
  • 11.17. Sanofi
    • 11.17.1. Company Overview
    • 11.17.2. Financial Performance
    • 11.17.3. Product Benchmarking
    • 11.17.4. Recent Development
  • 11.18. Teva Pharmaceutical
    • 11.18.1. Company Overview
    • 11.18.2. Financial Performance
    • 11.18.3. Product Benchmarking
    • 11.18.4. Recent Development